Skip to content
COVIDRIVE
  • Home
  • Study Contributors
  • Studies
  • Governance
  • Participate
  • Publications / Tools
    • Study documents
    • Publications
    • Drive Sample Size
    • Newsroom
  • Contact

Author: COVIDRIVE consortium

July 14, 2023August 1, 2023

COVIDRIVE has reached a milestone: enrolment of over 10,000 patients

Newsroom by COVIDRIVE consortium0 comments

We are pleased to announce that the first COVIDRIVE study has recruited 10,038 patients across 17 hospitals in 5 European countries.    This high recruitment number is important […]

Read more>>
July 1, 2023July 11, 2023

Pfizer Inc. has joined COVIDRIVE

Newsroom by COVIDRIVE consortium0 comments

July, 01 2023 – Pfizer has joined the COVIDRIVE Consortium and officially become a COVIDRIVE partner. Pfizer will further contribute […]

Read more>>
June 30, 2023July 18, 2023

AstraZeneca has published its first COVIDRIVE results in Lancet Regional Health Europe.

Newsroom by COVIDRIVE consortium0 comments

The study concluded that primary-series vaccination with AstraZeneca´s COVID-19 vaccine confers protection against COVID-19 hospitalisation with enduring levels of vaccine […]

Read more>>
Study investigator meeting in Copenhagen
April 16, 2023May 2, 2023

Study investigator meeting in Copenhagen

Newsroom by COVIDRIVE consortium0 comments

On 16 April, 2023, during the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Copenhagen, Denmark, a hybrid […]

Read more>>
April 5, 2023May 2, 2023

COVIDRIVE´s first German study site has been activated

Newsroom by COVIDRIVE consortium0 comments

The Study Contributor Universitätsklinikum Frankfurt was activated on 05 April 2023.

Read more>>
December 5, 2022December 5, 2022

First face-to-face COVIDRIVE Steering Committee meeting

Newsroom by COVIDRIVE consortium0 comments

On November 14th and 15th, 2022, the city of Valencia became the epicentre of COVIDRIVE Partnership discussions. The members of the COVIDRIVE Steering Committee (SC) connected to share the vaccine company-specific COVID-19 vaccine effectiveness interim results, to review all progress made and to brainstorm about vaccination preparedness and sustainability of the COVIDRIVE consortium. The group met at the Hotel Las Arenas and went through a packed two-day agenda.

Read more>>
July 13, 2022February 25, 2023

COVIDRIVE welcomes one new vaccine company to the consortium

Newsroom by COVIDRIVE consortium0 comments

13 July 2022 – Bavarian Nordic has joined the COVIDRIVE consortium and officially become
COVIDRIVE partner. Bavarian Nordic will further contribute to the assessment of the
effectiveness of COVID-19 vaccines in Europe to support the region’s public health response and
address the vaccine companies’ regulatory obligations.

Read more>>
February 8, 2022February 8, 2022

COVIDRIVE welcomes three new vaccine companies to the consortium

Newsroom by COVIDRIVE consortium0 comments

Three new vaccine companies (Moderna, Novavax and Valneva) have joined the COVIDRIVE consortium and officially become COVIDRIVE partners. Moderna, Novavax and Valneva will further contribute to the assessment of the effectiveness of COVID-19 vaccines in Europe to support the region’s public health response and address the vaccine companies’ regulatory obligations.

Read more>>
Launch of an ambitious cross-pharma study by the public-private partnership ‘COVIDRIVE’: a multi-country European study to continuously monitor COVID-19 vaccine effectiveness against severe disease
September 17, 2021September 19, 2021

Launch of an ambitious cross-pharma study by the public-private partnership ‘COVIDRIVE’: a multi-country European study to continuously monitor COVID-19 vaccine effectiveness against severe disease

Newsroom by COVIDRIVE consortium0 comments

17/09/2021- COVIDRIVE, a long-term, multi-country, hospital-based study investigating the effectiveness of COVID-19 vaccines across Europe has recently begun with the successful recruitment of its first patient – at a site in Valencia (Spain).

COVIDRIVE consists of a unique, cross-pharma consortium of vaccine companies and research groups who are joining forces to collect real-world data on the effectiveness of COVID-19 vaccines. This first COVIDRIVE study will monitor for variants of concern and help provide answers to the critical questions relating to COVID-19 vaccine effectiveness, including duration of protection of the different vaccines, impact of additional vaccine doses and different vaccine combinations.

Read more>>
New public-private partnership COVIDRIVE to assess brand-specific COVID-19 vaccine effectiveness in Europe
July 19, 2021September 19, 2021

New public-private partnership COVIDRIVE to assess brand-specific COVID-19 vaccine effectiveness in Europe

Newsroom by COVIDRIVE consortium0 comments

19/07/2021  – A new public-private partnership – COVIDRIVE – announced today that it will begin studies to assess the effectiveness of multiple COVID-19 vaccines in Europe to support the region’s public health response and to address the vaccine companies’ regulatory obligations. This multi-stakeholder partnership brings together public institutions, small medium enterprises and vaccine companies, including FISABIO (Spain), P95 (Belgium), THL (Finland), AstraZeneca (UK), CureVac (Germany), Janssen (Belgium), Sanofi-Pasteur (France) and GSK (Belgium).

Read more>>

Recent Posts

  • COVIDRIVE has reached a milestone: enrolment of over 10,000 patients
  • Pfizer Inc. has joined COVIDRIVE
  • AstraZeneca has published its first COVIDRIVE results in Lancet Regional Health Europe.
  • Study investigator meeting in Copenhagen
  • COVIDRIVE´s first German study site has been activated

Recent Comments

    © Copyright 2021   |   COVIDRIVE   |   ALL RIGHTS RESERVED

     

    Proudly powered by WordPress | Theme: Airi by aThemes.